GSK Boosts Profit Forecasts After ‘Outstanding’ RSV Vaccine Launch
High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.
High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.
What's Your Reaction?
